Better Therapeutics (NASDAQ:BTTX – Get Free Report) will likely be posting its resultson Thursday, April 2nd. Analysts expect Better Therapeutics to post earnings of ($0.27) per share and revenue of $1.4340 million for the quarter.
Better Therapeutics Stock Up 100.0%
NASDAQ BTTX opened at $0.00 on Thursday. Better Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.00. The stock has a market cap of $8,116.00, a PE ratio of 0.00 and a beta of 0.96.
About Better Therapeutics
Better Therapeutics, Inc is a clinical-stage digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. Its lead product candidate, BT-001, is a behavior-change program delivered via a smartphone application, designed to address underlying drivers of type 2 diabetes and hypertension through cognitive behavioral therapy techniques. The company’s platform is built to engage patients in personalized lifestyle modification, leveraging real-time feedback and data analytics to support sustained clinical improvements.
BT-001 is being evaluated in pivotal clinical trials under FDA investigational device exemptions, with studies examining its impact on glycemic control and blood pressure reduction.
Recommended Stories
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
